Protein conjugate pneumococcal vaccines

In this editorial by Vana Spoulou and colleagues (30 March, pp 750-1), our zeal to avoid too much repetition of “protein conjugate pneumococcal vaccine” unfortunately may have led to some confusion. The first sentence of the second paragraph should have read: “The need for a strict, objective assessment of the vaccine is further enhanced by serious concerns raised recently when pneumococcal polysaccharide vaccine [not “this vaccine”] was unexpectedly found to increase the rates of pneumonia in HIV infected individuals.²”